Thomas G.P. Bumm

TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms

Angela G. Fleischman, Karl J. Aichberger, Samuel B. Luty et al. · Blood · 2011 · 287 citations · Full text

Veterinary Medicine, Hematology, Immunology +13

Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking

Friederike Braig, Anna Brandt, Mariele Goebeler et al. · Blood · 2016 · 261 citations

Life Sciences, Immunology, Oncology +16

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

Jeffrey Tyner, Thomas G.P. Bumm, Jutta Deininger et al. · Blood · 2010 · 236 citations · Full text

Medicine, Hematology, Pharmacology +17

Emergence of clonal cytogenetic abnormalities in Ph−cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority

Thomas G.P. Bumm, Christel Müller, Haifa Kathrin Al‐Ali et al. · Blood · 2003 · 221 citations

Life Sciences, Genetics, Hematology +16

Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib

Ian J. Griswold, Mary MacPartlin, Thomas G.P. Bumm et al. · Molecular and Cellular Biology · 2006 · 199 citations · Full text

Medicine, Molecular Biology, Oncology +13